Phase III clinical trial - Appareil pulmonaire

AMGEN_20210004 (AMG 757)
Appareil pulmonaire
Essai clinique fermé
Public cible
Adulte
A Randomized, Open-label, Phase 3 Study of;Tarlatamab Compared With Standard of Care in;Subjects With Relapsed Small Cell Lung Cancer;After Platinum-based First-line Chemotherapy;(DeLLphi-304)
Description de l'essai
Evaluate the severity and impact of;symptomatic toxicity of tarlatamab and;SOC.
Liens utiles
Lien de l'essai
Vignette
NICOLAS GIRARD
Investigateur principal